The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ghanshyam Jaju
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ghanshyam Jaju, a promoter of Godavari Drugs Ltd, acquired 1,80,000 convertible warrants through a preferential allotment on 18th March 2026, valued at Rs. 7,53,06,000. Before the acquisition, he held 3,50,000 equity shares (4.65% voting rights). After the allotment, his total holding — shares plus warrants — stands at 5,30,000, representing 3.46% of current voting capital and 4.24% on a fully diluted basis (assuming full conversion of warrants). The filing was made under SEBI's SAST Regulation 29(2) for disclosure of the acquisition, and a related disclosure was also filed under SEBI's Insider Trading Regulation 6(2).
This is a promoter-led increase in stake, generally seen as a confidence signal from the promoter. However, the post-allotment voting stake is modest (3.46%), and the warrants are not yet shares, so any meaningful boost to promoter control will depend on future conversion.